Highlights Organon & Co.

Equities

OGN

US68622V1061

Real-time Estimate Cboe BZX Other stock markets 10:01:13 10/05/2024 pm IST			5-day change	1st Jan Change
20.36 ^USD	+0.67%		+3.85%	+41.23%

08/05	Organon Reports Pricing of $1 Billion Senior Notes Offering	MT
08/05	Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organon Reports Pricing of $1 Billion Senior Notes Offering	08/05	MT
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion	07/05	MT
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained	02/05	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B	02/05	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93	02/05	MT
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Organon & Co. Provides Earnings Guidance for the Year 2023	02/05	CI
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024	02/05	CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08/04	MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20/03	MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02	CI
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15/02	MT
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02	CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	15/02	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83	15/02	MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	15/02	CI
Organon & Co. Provides Earnings Guidance for the Year 2024	15/02	CI
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	10/01	CI
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump	08/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Organon & Co.

Equities

OGN

US68622V1061

Highlights

Filters